Almitan6.25 mg

Almitan 6.25 mg is a selective serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the following:

FDA-Approved / Established Use

• Acute treatment of migraine with or without aura in adults.
• Acute treatment of migraine headache pain in adolescents 12 to 17 years of age with a history of migraine and attacks typically lasting 4 hours or more when untreated.

Important Limitations

• Almitan 6.25 mg is intended only for the acute (abortive) treatment of a migraine attack that has already started; it is not indicated for migraine prophylaxis.
• Almitan 6.25 mg is not indicated for the treatment of cluster headache.
• A diagnosis of migraine should be clearly established before starting Almitan 6.25 mg.
• In adolescents, efficacy of Almitan 6.25 mg against migraine-associated symptoms (nausea, photophobia, phonophobia) has not been established.

Each film-coated tablet contains Almitan 6.25 mg malate equivalent to Almitan 6.25 mg 6.25 mg or 12.5 mg base.

Almitan 6.25 mg is an orally administered, selective serotonin 5-HT1B/1D receptor agonist belonging to the triptan class of antimigraine agents. It is used for the acute relief of migraine headache and associated symptoms. Almitan 6.25 mg is supplied as film-coated tablets for oral use and is intended to be taken as soon as possible after the onset of a migraine attack.

Triptan — Selective serotonin 5-HT1B/1D receptor agonist (antimigraine preparation). Almitan 6.25 mg belongs to this class.

Almitan 6.25 mg is a selective agonist at serotonin 5-HT1B and 5-HT1D receptors. Activation of these receptors on intracranial extracerebral blood vessels causes vasoconstriction, and activation of 5-HT1D receptors on trigeminal sensory nerve terminals inhibits the release of pro-inflammatory neuropeptides (such as CGRP), reducing neurogenic inflammation and pain transmission associated with migraine.

Pharmacokinetics

• Absorption: Oral bioavailability of Almitan 6.25 mg is approximately 70%; peak plasma concentration is reached in about 1–3 hours.
• Metabolism: Eliminated by two main pathways — monoamine oxidase-A (MAO-A) metabolism and CYP3A4-mediated oxidation, along with renal excretion of unchanged drug.
• Elimination half-life: Approximately 3–4 hours.
• Excretion: Roughly 40% is excreted unchanged in urine; the remainder as metabolites in urine and feces.

Almitan 6.25 mg tablets should be swallowed whole with water, with or without food, as soon as possible after the onset of migraine headache. Do not exceed the recommended dose or frequency. Almitan 6.25 mg is intended for treatment of an existing attack, not for prevention.

The following clinically significant interactions have been established with Almitan 6.25 mg:

• Ergot-containing or ergot-type medications (e.g., dihydroergotamine, ergotamine, methysergide): additive vasoconstrictive effects; do not use within 24 hours of Almitan 6.25 mg.
• Other triptans (5-HT1 agonists): additive vasoconstrictive effects; do not use within 24 hours of Almitan 6.25 mg.
• SSRIs and SNRIs: concurrent use with Almitan 6.25 mg carries a risk of serotonin syndrome (mental status changes, autonomic instability, neuromuscular abnormalities, gastrointestinal symptoms); monitor closely, especially at treatment initiation.
• Monoamine oxidase inhibitors (MAOIs): can alter the metabolism and increase systemic exposure of Almitan 6.25 mg; concurrent use should generally be avoided (see Contraindications).
• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): can increase Almitan 6.25 mg plasma levels by roughly 60%; a reduced dose is recommended (see Dosage and Administration).

The most commonly reported adverse effects of Almitan 6.25 mg are generally mild and transient.

Common (Adults)

• Nausea
• Dry mouth
• Paresthesia (tingling sensation)

Common (Adolescents)

• Dizziness
• Somnolence (drowsiness)
• Headache
• Nausea and vomiting

Less Common

• Palpitations, chest discomfort, flushing/vasodilation
• Dyspepsia, diarrhea
• Drowsiness, tremor, anxiety
• Rash, sweating, itching

Rare but Serious

• Serotonin syndrome (see Precautions and Warnings)
• Serious cardiac events including myocardial infarction, coronary vasospasm, and arrhythmias
• Anaphylaxis/angioedema
• Cerebrovascular events (stroke, hemorrhage)

Patients experiencing chest, throat, neck, or jaw tightness/pain after taking Almitan 6.25 mg should seek prompt medical evaluation.

Pregnancy: There are no adequate and well-controlled studies of Almitan 6.25 mg in pregnant women. Animal studies have shown developmental toxicity at doses substantially higher than the maximum recommended human dose. Almitan 6.25 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Almitan 6.25 mg is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised, and a physician should be consulted, when considering Almitan 6.25 mg use during breastfeeding.

Cardiovascular risk assessment: Before prescribing Almitan 6.25 mg, patients should be evaluated for underlying cardiovascular disease, particularly those with risk factors such as hypertension, hypercholesterolemia, smoking, obesity, diabetes, family history of coronary artery disease, postmenopausal status, or men over 40. For patients with multiple risk factors, consider administering the first dose of Almitan 6.25 mg under medical supervision, with ECG monitoring if appropriate.

Chest, throat, neck, or jaw symptoms: Sensations of tightness, pain, or pressure can occur after taking Almitan 6.25 mg and typically resolve; if intense or persistent, cardiac evaluation is required before further doses.

Cerebrovascular events: Rare cases of stroke and hemorrhage have been reported with triptans, including Almitan 6.25 mg; rule out other causes of the headache before treatment, particularly in patients not previously diagnosed with migraine.

Serotonin syndrome: Risk increases with concurrent SSRIs, SNRIs, or MAOIs (see Interactions and Contraindications).

Blood pressure: Almitan 6.25 mg may cause a transient increase in blood pressure; it is contraindicated in uncontrolled hypertension.

Sulfonamide sensitivity: Use with caution in patients with known sulfonamide allergy, as Almitan 6.25 mg malate contains a sulfonamide moiety, although cross-reactivity has not been systematically studied.

Renal/hepatic impairment: Dose reduction is required (see Dosage and Administration).

Medication-overuse headache: Frequent or excessive use of Almitan 6.25 mg (more than about 10 days per month) can lead to medication-overuse headache; limit the frequency of use and consult a physician if headaches worsen or increase in frequency.

Limited data are available on overdose with Almitan 6.25 mg. Based on the pharmacology of triptans, overdose may cause hypertension or other cardiovascular symptoms. In case of suspected overdose of Almitan 6.25 mg, seek immediate medical attention or contact emergency services/a poison control center. Clinical and electrocardiographic monitoring should be continued for at least 20 hours, even if symptoms are not evident, due to the possibility of delayed cardiovascular effects. Treatment is supportive; the effect of dialysis on Almitan 6.25 mg removal is not established.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: In patients with severe renal impairment, start with a lower dose of Almitan 6.25 mg (6.25 mg) with a maximum of 12.5 mg in 24 hours.

Hepatic impairment: In patients with hepatic impairment, start with a lower dose of Almitan 6.25 mg (6.25 mg) with a maximum of 12.5 mg in 24 hours.

Elderly: Clinical experience with Almitan 6.25 mg in patients over 65 years is limited; cardiovascular risk should be carefully assessed before use, as advanced age is itself a cardiovascular risk factor.

Pediatric patients (under 12 years): Safety and efficacy of Almitan 6.25 mg have not been established.

Adolescents (12–17 years): Use is established only for acute headache pain relief, using the same dosing as adults (see Dosage and Administration).

Almitan 6.25 mg is intended for short-term, as-needed (per-attack) use only and is not intended for chronic daily administration or migraine prevention. Treatment with Almitan 6.25 mg should be limited to no more than about 10 days per month to reduce the risk of medication-overuse headache. If migraine attacks become more frequent or treatment is needed on more days than this, consult a physician for reassessment and consideration of preventive therapy.

Triptans (selective serotonin 5-HT1B/1D receptor agonists); antimigraine agents. Almitan 6.25 mg is a member of this drug class.

Almitan 6.25 mg acts as a selective agonist at 5-HT1B and 5-HT1D serotonin receptors. This causes constriction of dilated intracranial extracerebral blood vessels believed to be involved in migraine, and inhibits the release of vasoactive, pro-inflammatory neuropeptides (such as calcitonin gene-related peptide) from trigeminal sensory nerves, thereby reducing neurogenic inflammation and interrupting migraine pain transmission.

C

Safety and efficacy of Almitan 6.25 mg in children under 12 years of age have not been established, and Almitan 6.25 mg is not recommended for this age group.

In adolescents 12 to 17 years of age, Almitan 6.25 mg has been evaluated for the acute treatment of migraine headache pain, with a safety profile similar to that seen in adults; however, efficacy against associated symptoms (nausea, photophobia, phonophobia) has not been established in this age group. Dosing in adolescents follows the same recommendations as for adults (see Dosage and Administration).